Back to Search Start Over

Progress in elucidating pathophysiology of mucolipidosis IV.

Authors :
Misko A
Wood L
Kiselyov K
Slaugenhaupt S
Grishchuk Y
Source :
Neuroscience letters [Neurosci Lett] 2021 Jun 11; Vol. 755, pp. 135944. Date of Electronic Publication: 2021 May 11.
Publication Year :
2021

Abstract

Mucolipidosis IV (MLIV) is an autosomal-recessive disease caused by loss-of-function mutations in the MCOLN1 gene encoding the non-selective cationic lysosomal channel transient receptor potential mucolipin-1 (TRPML1). Patients with MLIV suffer from severe motor and cognitive deficits that manifest in early infancy and progressive loss of vision leading to blindness in the second decade of life. There are no therapies available for MLIV and the unmet medical need is extremely high. Here we review the spectrum of clinical presentations and the latest research in the MLIV pre-clinical model, with the aim of highlighting the progress in understanding the pathophysiology of the disease. These highlights include elucidation of the neurodevelopmental versus neurodegenerative features over the course of disease, hypomyelination as one of the major brain pathological disease hallmarks, and dysregulation of cytokines, with emerging evidence of IFN-gamma pathway upregulation in response to TRPML1 loss and pro-inflammatory activation of astrocytes and microglia. These scientific advances in the MLIV field provide a basis for future translational research, including biomarker and therapy development, that are desperately needed for this patient population.<br /> (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1872-7972
Volume :
755
Database :
MEDLINE
Journal :
Neuroscience letters
Publication Type :
Academic Journal
Accession number :
33965501
Full Text :
https://doi.org/10.1016/j.neulet.2021.135944